Traws Net Income From Continuing Ops from 2010 to 2024

TRAW Stock   5.02  0.31  5.82%   
Traws Pharma Net Loss yearly trend continues to be fairly stable with very little volatility. Net Loss will likely drop to about -19.9 M in 2024. During the period from 2010 to 2024, Traws Pharma Net Loss regression line of quarterly data had r-squared of  0.51 and coefficient of variation of (13.43). View All Fundamentals
 
Net Loss  
First Reported
2010-12-31
Previous Quarter
-18.9 M
Current Value
-19.9 M
Quarterly Volatility
3.1 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Traws Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Traws Pharma's main balance sheet or income statement drivers, such as Tax Provision of 0.0, Depreciation And Amortization of 15.6 K or Total Revenue of 193.2 K, as well as many indicators such as Price To Sales Ratio of 1.1 K, Dividend Yield of 0.0 or PTB Ratio of 30.16. Traws financial statements analysis is a perfect complement when working with Traws Pharma Valuation or Volatility modules.
  
Check out the analysis of Traws Pharma Correlation against competitors.
For more information on how to buy Traws Stock please use our How to Invest in Traws Pharma guide.

Latest Traws Pharma's Net Income From Continuing Ops Growth Pattern

Below is the plot of the Net Income From Continuing Ops of Traws Pharma over the last few years. It is Traws Pharma's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Traws Pharma's overall financial position and show how it may be relating to other accounts over time.
Net Income From Continuing Ops10 Years Trend
Slightly volatile
   Net Income From Continuing Ops   
       Timeline  

Traws Net Income From Continuing Ops Regression Statistics

Arithmetic Mean(23,379,827)
Coefficient Of Variation(13.43)
Mean Deviation2,606,521
Median(25,157,000)
Standard Deviation3,140,817
Sample Variance9.9T
Range9M
R-Value0.72
Mean Square Error5.2T
R-Squared0.51
Significance0
Slope503,665
Total Sum of Squares138.1T

Traws Net Income From Continuing Ops History

2024-19.9 M
2023-18.9 M
2022-19 M
2021-16.2 M

About Traws Pharma Financial Statements

Traws Pharma investors use historical fundamental indicators, such as Traws Pharma's Net Income From Continuing Ops, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Traws Pharma. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Net Loss-18.9 M-19.9 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Traws Stock Analysis

When running Traws Pharma's price analysis, check to measure Traws Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Traws Pharma is operating at the current time. Most of Traws Pharma's value examination focuses on studying past and present price action to predict the probability of Traws Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Traws Pharma's price. Additionally, you may evaluate how the addition of Traws Pharma to your portfolios can decrease your overall portfolio volatility.